Patents by Inventor Nessan A. Bermingham

Nessan A. Bermingham has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RNA-Editing Oligonucleotides and Uses Thereof
    Publication number: 20230340464
    Abstract: The present disclosure features useful compositions and methods to treat disorders for which deamination of an adenosine in an mRNA produces a therapeutic result.
    Type: Application
    Filed: May 3, 2023
    Publication date: October 26, 2023
    Applicant: Korro Bio, Inc.
    Inventors: Andrew W. Fraley, Steven Robinette, Nessan Bermingham, Mallikarjuna Reddy Putta
  • RNA-Editing Oligonucleotides and Uses Thereof
    Publication number: 20230332143
    Abstract: The present disclosure features useful compositions and methods to treat disorders for which deamination of an adenosine in an mRNA produces a therapeutic result, e.g., in a subject in need thereof.
    Type: Application
    Filed: May 9, 2023
    Publication date: October 19, 2023
    Applicant: Korro Bio, Inc.
    Inventors: Andrew W. Fraley, Steven Robinette, Nessan Bermingham, Mallikarjuna Reddy Putta
  • RNA-Editing Oligonucleotides and Uses Thereof
    Publication number: 20230146891
    Abstract: The present disclosure features useful compositions and methods to treat disorders for which deamination of an adenosine in an mRNA produces a therapeutic result, e.g., in a subject in need thereof.
    Type: Application
    Filed: September 15, 2022
    Publication date: May 11, 2023
    Applicant: Korro Bio, Inc.
    Inventors: Andrew W. Fraley, Steven Robinette, Nessan Bermingham, Mallikarjuna Reddy Putta
  • RNA-Editing Oligonucleotides and Uses Thereof
    Publication number: 20230104978
    Abstract: The present disclosure features useful compositions and methods to treat disorders for which deamination of an adenosine in an mRNA produces a therapeutic result,
    Type: Application
    Filed: August 5, 2022
    Publication date: April 6, 2023
    Applicant: Korro Bio, Inc.
    Inventors: Andrew W. Fraley, Steven Robinette, Nessan Bermingham, Mallikarjuna Reddy Putta
  • RNA-editing oligonucleotides and uses thereof
    Patent number: 11479575
    Abstract: The present disclosure features useful compositions and methods to treat disorders for which deamination of an adenosine in an mRNA produces a therapeutic result, e.g., in a subject in need thereof.
    Type: Grant
    Filed: January 22, 2020
    Date of Patent: October 25, 2022
    Assignee: Korro Bio, Inc.
    Inventors: Andrew W. Fraley, Steven Robinette, Nessan Bermingham, Mallikarjuna Reddy Putta
  • RNA-editing oligonucleotides and uses thereof
    Patent number: 11453878
    Abstract: The present disclosure features useful compositions and methods to treat disorders for which deamination of an adenosine in an mRNA produces a therapeutic result, e.g., in a subject in need thereof.
    Type: Grant
    Filed: January 22, 2020
    Date of Patent: September 27, 2022
    Assignee: Korro Bio, Inc.
    Inventors: Andrew W. Fraley, Steven Robinette, Nessan Bermingham, Mallikarjuna Reddy Putta
  • RNA-EDITING OLIGONUCLEOTIDES AND USES THEREOF
    Publication number: 20200399303
    Abstract: The present disclosure features useful compositions and methods to treat disorders for which deamination of an adenosine in an mRNA produces a therapeutic result, e.g., in a subject in need thereof.
    Type: Application
    Filed: January 22, 2020
    Publication date: December 24, 2020
    Inventors: Andrew W. FRALEY, Steven ROBINETTE, Nessan BERMINGHAM, Mallikarjuna Reddy PUTTA
  • RNA-EDITING OLIGONUCLEOTIDES AND USES THEREOF
    Publication number: 20200392486
    Abstract: The present disclosure features useful compositions and methods to treat disorders for which deamination of an adenosine in an mRNA produces a therapeutic result, e.g., in a subject in need thereof.
    Type: Application
    Filed: January 22, 2020
    Publication date: December 17, 2020
    Inventors: Andrew W. FRALEY, Steven ROBINETTE, Nessan BERMINGHAM, Mallikarjuna Reddy PUTTA
  • RNA-EDITING OLIGONUCLEOTIDES AND USES THEREOF
    Publication number: 20200385713
    Abstract: The present disclosure features useful compositions and methods to treat disorders for which deamination of an adenosine in an mRNA produces a therapeutic result, e.g., in a subject in need thereof.
    Type: Application
    Filed: January 22, 2020
    Publication date: December 10, 2020
    Inventors: Andrew W. FRALEY, Steven ROBINETTE, Nessan BERMINGHAM, Mallikarjuna Reddy PUTTA
  • Composition and methods for the therapeutic use of an atonal-associated sequence for deafness, osteoarthritis and abnormal cell proliferation
    Patent number: 7470673
    Abstract: Compositions and methods are disclosed for the therapeutic use of an atonal-associated nucleic acid or amino acid sequence. Also, an animal heterozygous for an atonal-associated gene inactivation is also disclosed having at least one atonal-associated nucleic acid sequence replaced by insertion of a heterologous nucleic acid sequence used to detect expression driven by an atonal-associated promoter sequence, wherein the inactivation of the atonal-associated nucleic acid sequence prevents expression of the atonal-associated gene.
    Type: Grant
    Filed: June 3, 2004
    Date of Patent: December 30, 2008
    Assignee: Baylor College of Medicine
    Inventors: Huda Y. Zoghbi, Hugo Bellen, Nessan Bermingham, Bassem Hassan, Nissim Ben-arie
  • Composition and methods for the therapeutic use of an atonal-associated sequence for deafness, osteoarthritis and abnormal cell proliferation
    Patent number: 7442688
    Abstract: Compositions and methods are disclosed for the therapeutic use of an atonal-associated nucleic acid or amino acid sequence. Also, an animal heterozygous for an atonal-associated gene inactivation is also disclosed having at least one atonal-associated nucleic acid sequence replaced by insertion of a heterologous nucleic acid sequence used to detect expression driven by an atonal-associated promoter sequence, wherein the inactivation of the atonal-associated nucleic acid sequence prevents expression of the atonal-associated gene.
    Type: Grant
    Filed: June 3, 2004
    Date of Patent: October 28, 2008
    Assignee: Baylor College of Medicine
    Inventors: Huda Y. Zoghbi, Hugo Bellen, Nessan Bermingham, Bassem Hassan, Nissim Ben-arie
  • Compositions and methods for the therapeutic use of an atonal-associated sequence for deafness, osteoarthritis, and abnormal cell proliferation
    Patent number: 7053200
    Abstract: Compositions and methods are disclosed for the therapeutic use of an atonal-associated nucleic acid or amino acid sequence. Also, an animal heterozygous for an atonal-associated gene inactivation is also disclosed having at least one atonal-associated nucleic acid sequence replaced by insertion of a heterologous nucleic acid sequence used to detect expression driven by an atonal-associated promoter sequence, wherein the inactivation of the atonal-associated nucleic acid sequence prevents expression of the atonal-associated gene.
    Type: Grant
    Filed: June 1, 2000
    Date of Patent: May 30, 2006
    Assignee: Baylor College of Medicine
    Inventors: Huda Y. Zoghbi, Hugo Bellen, Nessan Bermingham, Bassem Hassan, Nissim Ben-arie
  • Compositions and methods for the therapeutic use of an atonal-associated sequence for deafness, osteoarthritis, and abnormal cell proliferation
    Patent number: 6838444
    Abstract: Compositions and methods are disclosed for the therapeutic use of an atonal-associated nucleic acid or amino acid sequence. Also, an animal heterozygous for an atonal-associated gene inactivation is also disclosed having at least one atonal-associated nucleic acid sequence replaced by insertion of a heterologous nucleic acid sequence used to detect expression driven by an atonal-associated promoter sequence, wherein the inactivation of the atonal-associated nucleic acid sequence prevents expression of the atonal-associated gene.
    Type: Grant
    Filed: June 1, 2000
    Date of Patent: January 4, 2005
    Assignee: Baylor College of Medicine
    Inventors: Huda Y. Zoghbi, Hugo J. Bellen, Nessan A. Bermingham, Bassem Hassan, Nissim Ben-Arie
  • Composition and methods for the therapeutic use of an atonal-associated sequence for deafness, osteoarthritis and abnormal cell proliferation
    Publication number: 20040237127
    Abstract: Compositions and methods are disclosed for the therapeutic use of an atonal-associated nucleic acid or amino acid sequence. Also, an animal heterozygous for an atonal-associated gene inactivation is also disclosed having at least one atonal-associated nucleic acid sequence replaced by insertion of a heterologous nucleic acid sequence used to detect expression driven by an atonal-associated promoter sequence, wherein the inactivation of the atonal-associated nucleic acid sequence prevents expression of the atonal-associated gene.
    Type: Application
    Filed: June 3, 2004
    Publication date: November 25, 2004
    Inventors: Huda Y. Zoghbi, Hugo J. Bellen, Nessan A. Bermingham, Bassem Hassan, Nissim Ben-Arie
  • Composition and methods for the therapeutic use of an atonal-associated sequence for deafness, osteoarthritis and abnormal cell proliferation
    Publication number: 20040231009
    Abstract: Compositions and methods are disclosed for the therapeutic use of an atonal-associated nucleic acid or amino acid sequence. Also, an animal heterozygous for an atonal-associated gene inactivation is also disclosed having at least one atonal-associated nucleic acid sequence replaced by insertion of a heterologous nucleic acid sequence used to detect expression driven by an atonal-associated promoter sequence, wherein the inactivation of the atonal-associated nucleic acid sequence prevents expression of the atonal-associated gene.
    Type: Application
    Filed: June 3, 2004
    Publication date: November 18, 2004
    Inventors: Huda Y. Zoghbi, Hugo J. Bellen, Nessan A. Bermingham, Bassem Hassan, Nissim Ben-Arie